Heart failure with a preserved ejection fraction（HFpEF）is characterized by incomplete relaxation and reduced compliance of cardiomyocytes. HFpEF patients make up 50% of all chronic heart failure patients, about 225,000 in China. The five-year mortality rate of HFpEF patients is 50%, which is the same for HFrEF (Heart Failure reduced ejection fraction) patients. There is no evidence that the drugs currently available could reduce the morbidity and mortality rates in HFpEF patients, until now.
The effect of Neucardin® on cardiomyocytes brings hope that there could be a treatment for HFpEF. Preclinical research shows that Neucardin® improves left ventricular compliance in spontaneously hypertensive rats, reduces Ca2+ overload of animal model, and results in a higher maximum speed of instant decrease of Ca2+ during diastole in rats with chronic heart failure induced by spontaneous hypertension. In Neucardin® clinical trials for HFrEF treatment, data shows that Neucardin® could reverse ventricular remodeling. Therefore, Neucardin® is very promising to be the first drug curing HFpEF in history. Now Zensun is preparing for a phase II clinical trial for this indication.